Antibody–drug conjugates (ADCs) represent a significant advancement in targeted therapeutics, but their analytical characterization remains a challenge in biopharmaceutical development.

Unlike traditional monoclonal antibodies, ADCs combine an antibody backbone with linker chemistry and a cytotoxic payload. This multi-component architecture introduces overlapping layers of heterogeneity, including drug-to-antibody ratio (DAR) distributions, charge variants, post-translational modifications, and structural changes at both the intact and subunit levels. Across ADC development, these characteristics are considered critical quality attributes that must be characterized, understood, and monitored.

The challenge is not only detecting this heterogeneity but interpreting its underlying causes and impact on product quality. Traditional analytical approaches often rely on multiple orthogonal techniques, each providing only a partial view. Intact mass analysis can quantify DAR, whereas electrophoretic methods like cIEF, CZE, or CE-SDS reveal charge heterogeneity or purity, and peptide mapping identifies structural modifications. However, without a way to connect these measurements, critical questions remain unanswered, such as:

• Which specific molecular species are present?
• What structural feature is driving an observed change?
• How does a given variant affect stability, efficacy, or safety?

This fragmentation of analytical insight leads to a common bottleneck in ADC development: increasing analytical effort without a proportional increase in decision confidence.

At the same time, ADC complexity continues to evolve. Modern conjugation strategies introduce subtle structural variations, labile payload modifications, and low-abundance species that are difficult to resolve. For example, accurately localizing payload attachment sites or differentiating closely related isomers often requires advanced fragmentation approaches that preserve sensitive modifications. SCIEX LC-MS workflows demonstrate that techniques such as electron-activated dissociation (EAD) can enable confident localization of post-translational modifications, glycosylation patterns, and conjugation sites, capabilities essential for understanding ADC structure at the molecular level.

In parallel, charge heterogeneity remains a persistent analytical challenge. ADC conjugation frequently alters the molecule’s charge profile, introducing additional variants that can obscure interpretation. Integrated approaches such as icIEF‑UV/MS provide a more complete picture by combining high-resolution separation with direct mass confirmation, enabling analysts to move from observing charge shifts to explaining their molecular origin.

Structural integrity adds another dimension. High-throughput, reproducible CE‑based methods, demonstrated on the BioPhase 8800 system, enable robust purity assessment and support method transfer to the PA 800 Plus system in QC environments, ensuring continuity from development through manufacturing.

These challenges highlight a broader shift in ADC analytics. Success is no longer defined by the number of attributes measured, but by the ability to connect those attributes into a coherent, decision-ready understanding of molecular heterogeneity.

SCIEX addresses this need through, multi-attribute workflows that span intact, subunit, and peptide-level analysis. By combining orthogonal separation techniques such as CE and icIEF with high-resolution mass spectrometry and advanced fragmentation strategies like EAD, these workflows enable a unified view of ADC heterogeneity, linking structure to function with greater clarity and confidence.

Ready to learn more? Download the eBook >

Want to discuss your ADC workflow?
Connect with a SCIEX expert to explore analytical strategies for charge heterogeneity, DAR analysis, payload localization, structural characterization, and quantitative ADC workflows.
Request more info >